1. Senescence and the tumor-immune landscape: Implications for cancer ...
Cancer therapies, including conventional chemotherapy, radiation, and molecularly targeted agents, can lead to tumor eradication through a variety of ...
Cancer therapies, including conventional chemotherapy, radiation, and molecularly targeted agents, can lead to tumor eradication through a variety of mechanisms. In addition to their effects on tumor cell growth and survival, these regimens can also ...
2. MIRACUM-Pipe: An Adaptable Pipeline for Next-Generation ... - NCBI
1 jul 2023 · An adaptable pipeline for next-generation sequencing analysis, reporting, and visualization for clinical decision making.
Next-generation sequencing (NGS) is a cutting-edge technology that enables rapid, high-throughput sequencing of DNA and RNA. Researchers and clinicians can identify genetic mutations, gene fusions, and other alterations that may drive cancer growth. ...
3. Regulation of Bim in Health and Disease - Oncotarget
15 sep 2015 · This review focuses on the intricate network regulating Bim activity and its involvement in physiological and pathophysiological processes.
// Ronit Vogt Sionov 1 , Spiros A. Vlahopoulos 2 and Zvi Granot 1 1 Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel Canada, Hebrew University, Hadassah Medical School, Jerusalem, Israel 2 First Department of Pediatrics, University of Athens, Horemeio Research Laboratory, Thivon and Levadias, Goudi, Athens, Greece Correspondence to: Ronit Vogt Sionov, email: // Keywords : Bim, apoptosis, cancer, autoimmunity, neurodegenerative diseases Received : July 28, 2015 Accepted : August 08, 2015 Published : September 05, 2015 Abstract The BH3-only Bim protein is a major determinant for initiating the intrinsic apoptotic pathway under both physiological and pathophysiological conditions. Tight regulation of its expression and activity at the transcriptional, translational and post-translational levels together with the induction of alternatively spliced isoforms with different pro-apoptotic potential, ensure timely activation of Bim. Under physiological conditions, Bim is essential for shaping immune responses where its absence promotes autoimmunity, while too early Bim induction eliminates cytotoxic T cells prematurely, resulting in chronic inflammation and tumor progression. Enhanced Bim induction in neurons causes neurodegenerative disorders including Alzheimer’s, Parkinson’s and Huntington’s diseases. Moreover, type I diabetes is promoted by genetically predisposed elevation of Bim in...
4. Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New ...
Here, we review the landscape of currently available direct apoptosis-targeting agents in clinical development for cancer treatment and update the related ...
Evasion from apoptosis is an important hallmark of cancer cells. Alterations of apoptosis pathways are especially critical as they confer resistance to conventional anti-cancer therapeutics, e.g., chemotherapy, radiotherapy, and targeted therapeutics. Thus, successful induction of apoptosis using novel therapeutics may be a key strategy for preventing recurrence and metastasis. Inhibitors of anti-apoptotic molecules and enhancers of pro-apoptotic molecules are being actively developed for hematologic malignancies and solid tumors in particular over the last decade. However, due to the complicated apoptosis process caused by a multifaceted connection with cross-talk pathways, protein–protein interaction, and diverse resistance mechanisms, drug development within the category has been extremely challenging. Careful design and development of clinical trials incorporating predictive biomarkers along with novel apoptosis-inducing agents based on rational combination strategies are needed to ensure the successful development of these molecules. Here, we review the landscape of currently available direct apoptosis-targeting agents in clinical development for cancer treatment and update the related biomarker advancement to detect and validate the efficacy of apoptosis-targeted therapies, along with strategies to combine them with other agents.
5. Silke Gillessen - European Society for Medical Oncology
Professor Silke Gillessen is a Medical Oncologist with focus on genitourinary cancer. She completed her training in Basel, St. Gallen, and the Dana Farber ...
Professor Silke Gillessen is a Medical Oncologist with focus on genitourinary cancer.
6. Prostacyclin Released by Cancer-Associated Fibroblasts ...
We found that prostacyclin is mainly secreted by cancer-associated fibroblast and selectively acts on prostacyclin receptor-expressing macrophages to induce ...
Metastasis of high-grade ovarian carcinoma (HGSC) is orchestrated by soluble mediators of the tumor microenvironment. Here, we have used transcriptomic profiling to identify lipid-mediated signaling pathways encompassing 41 ligand-synthesizing enzymes and 23 cognate receptors in tumor, immune and stroma cells from HGSC metastases and ascites. Due to its strong association with a poor clinical outcome, prostacyclin (PGI2) synthase (PTGIS) is of particular interest in this signaling network. PTGIS is highly expressed by cancer-associated fibroblasts (CAF), concomitant with elevated PGI2 synthesis, whereas tumor-associated macrophages (TAM) exhibit the highest expression of its surface receptor (PTGIR). PTGIR activation by PGI2 agonists triggered cAMP accumulation and induced a mixed-polarization macrophage phenotype with altered inflammatory gene expression, including CXCL10 and IL12A repression, as well as reduced phagocytic capability. Co-culture experiments provided further evidence for the interaction of CAF with macrophages via PGI2, as the effect of PGI2 agonists on phagocytosis was mitigated by cyclooxygenase inhibitors. Furthermore, conditioned medium from PGI2-agonist-treated TAM promoted tumor adhesion to mesothelial cells and migration in a PTGIR-dependent manner, and PTGIR activation induced the expression of metastasis-associated and pro-angiogenic genes. Taken together, our study identifies a PGI2/PTGIR-driven crosstalk between CAF, TAM and tumor cells, promoting...
7. 1867 - ClarIDHy: A global, phase 3, randomized, double-blind study of ...
30 sep 2019 · CC is a rare cancer for which there are limited effective therapies. IDH1 mutations occur in up to ∼15% of CC, resulting in production of the ...
OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,
8. ATM mutations and E-cadherin expression define sensitivity to ...
7 mrt 2017 · We here identify ATM and E-cadherin expression as potential novel supportive predictive markers for EGFR-targeted therapy.
// Anna-Lena Geißler 1, 2, 3, 4 , Miriam Geißler 1, 2, 3 , Daniel Kottmann 1, 2, 3 , Lisa Lutz 1, 2 , Christiane D. Fichter 1, 2, 3 , Ralph Fritsch 2, 5, 7 , Britta Weddeling 1, 7 , Frank Makowiec 2, 6, 7 , Martin Werner 1, 2, 4, 7 , Silke Lassmann 1, 2, 4, 7, 8 1 Institute of Surgical Pathology, University of Freiburg, Freiburg im Breisgau, Germany 2 Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany 3 Faculty of Biology, University of Freiburg, Freiburg im Breisgau, Germany 4 German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany 5 Department of Internal Medicine, University of Freiburg, Freiburg im Breisgau, Germany 6 Department of Surgery, University of Freiburg, Freiburg im Breisgau, Germany 7 Comprehensive Cancer Center Freiburg, All Medical Center – University of Freiburg, Freiburg im Breisgau, Germany 8 BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg im Breisgau, Germany Correspondence to: Silke Lassmann, email: silke.lassmann@uniklinik-freiburg.de Keywords: anti-EGFR therapy, next generation sequencing, predictive markers, colorectal cancer (CRC), E-cadherin Received: July 11, 2016 Accepted: January 16, 2017 Published: February 09, 2017 ABSTRACT EGFR-targeted therapy is a key treatment approach in patients with RAS wildtype...
